首页 / 院系成果 / 成果详情页

Peripheral CB1 Receptor Neutral Antagonist, AM6545, Ameliorates Hypometabolic Obesity and Improves Adipokine Secretion in Monosodium Glutamate Induced Obese Mice  期刊论文  

  • 编号:
    94b3d123-b9fa-4aec-b781-3dbbb3b9918c
  • 作者:
    Ma, Haiming(马海明)#*[1]Zhang, Guina[2];Mou, Chunrong[3];Fu, Xiujuan(付秀娟)[4]Chen, Yadan*[4]
  • 语种:
    英文
  • 期刊:
    FRONTIERS IN PHARMACOLOGY ISSN:1663-9812 2018 年 9 卷 ; MAR 20
  • 收录:
  • 关键词:
  • 摘要:

    Effect of peripheral cannabinoid receptor 1 (CB1R) blockade by AM6545 in the monosodium glutamate (MSG)-induced hypometabolic and hypothalamic obesity was observed, and the impact on intraperitoneal adipose tissue and adipokines was investigated. The MSG mice is characterized by excessive abdominal obesity, and combined with dyslipidemia and insulin resistance. 3-Week AM6545 treatment dose-dependently decreased the body weight, intraperitoneal fat mass, and rectified the accompanied dyslipidemia include elevated serum triglyceride, total cholesterol, free fatty acids, and lowered LDLc level. Glucose intolerance and hyperinsulinemia were also alleviated. But AM6545 didn't affect the food-intake consistently through the experiment. In line with the reduction on fat mass, the size of adipocyte was reduced markedly. Most interestingly, AM6545 showed significant improvement on levels of circulating adipokines including lowering leptin, asprosin and TNF alpha, and increasing HMW adiponectin. Correspondingly, dysregulated gene expression of lipogenesis, lipolysis, and adipokines in the adipose tissue were nearly recovered to normal level after AM6545 treatment. Additionally, western blot analysis revealed that AM6545 corrected the elevated CB1R and PPAR gamma protein expression, while increased the key energy uncoupling protein UCP1 expression in adipose tissue. Taken together, the current study indicates that AM6545 induced a comprehensive metabolic improvement in the MSG mice including counteracting the hypometabolic and hypothalamic obesity, and improving the accompanied dyslipidemia and insulin resistance. One key underlying mechanism is related to ameliorate on the metabolic deregulation of adipose tissue, the synthesis and secretion of adipokines were thus rectified, and finally the catabolism was increased and the anabolism was reduced in intraperitoneal adipose tissue. Findings from this study will provide the valuable information about peripheral CB1R antagonist in managing hypometabolic obesity.

  • 推荐引用方式
    GB/T 7714:
    Ma Haiming,Zhang Guina,Mou Chunrong, et al. Peripheral CB1 Receptor Neutral Antagonist, AM6545, Ameliorates Hypometabolic Obesity and Improves Adipokine Secretion in Monosodium Glutamate Induced Obese Mice [J].FRONTIERS IN PHARMACOLOGY,2018,9.
  • APA:
    Ma Haiming,Zhang Guina,Mou Chunrong,Fu Xiujuan,&Chen Yadan.(2018).Peripheral CB1 Receptor Neutral Antagonist, AM6545, Ameliorates Hypometabolic Obesity and Improves Adipokine Secretion in Monosodium Glutamate Induced Obese Mice .FRONTIERS IN PHARMACOLOGY,9.
  • MLA:
    Ma Haiming, et al. "Peripheral CB1 Receptor Neutral Antagonist, AM6545, Ameliorates Hypometabolic Obesity and Improves Adipokine Secretion in Monosodium Glutamate Induced Obese Mice" .FRONTIERS IN PHARMACOLOGY 9(2018).
  • 条目包含文件:
    文件类型:PDF,文件大小:
    正在加载全文
浏览次数:61 下载次数:0
浏览次数:61
下载次数:0
打印次数:0
浏览器支持: Google Chrome   火狐   360浏览器极速模式(8.0+极速模式) 
返回顶部